| P2093 | author name string | Lawrence Blonde | |
| | Zinnia T San Juan | |
| P2860 | cites work | Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. | Q51563377 |
| | Impact of dosage frequency on patient compliance. | Q53964327 |
| | Patient perspectives on multiple medications versus combined pills: a qualitative study | Q56783264 |
| | Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 |
| | Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study | Q28214017 |
| | Clinical outcomes and adherence to medications measured by claims data in patients with diabetes | Q30977056 |
| | Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature | Q33436395 |
| | Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 |
| | Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy | Q34656261 |
| | Fixed-dose combinations improve medication compliance: a meta-analysis. | Q34659858 |
| | Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components | Q34774198 |
| | Approaches to patient education: emphasizing the long-term value of compliance and persistence | Q36431210 |
| | Impact of fixed-dose combination drugs on adherence to prescription medications | Q36572787 |
| | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 |
| | Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. | Q37327697 |
| | Differences in psychometric properties, cut-off scores, and outcomes between the Barthel Index and Modified Rankin Scale in pharmacotherapy-based stroke trials: systematic literature review | Q37472147 |
| | Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control | Q37621774 |
| | Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice | Q39643925 |
| | The burden of treatment failure in type 2 diabetes | Q40500624 |
| | Fixed-dose combinations of antituberculous medications to prevent drug resistance | Q40528410 |
| | Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors | Q42171281 |
| | Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea | Q43108038 |
| | Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. | Q43261599 |
| | Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus | Q43738827 |
| | Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients | Q43938840 |
| | Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy | Q43958331 |
| | Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. | Q44016357 |
| | Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus | Q44354569 |
| | Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea | Q44507814 |
| | Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co‐administered with metformin | Q44655649 |
| | Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. | Q45974567 |
| | Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure | Q46847942 |
| | Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. | Q51467253 |
| | Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. | Q51471806 |
| | Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. | Q51488169 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 1-13 | |
| P577 | publication date | 2012-01-16 | |
| P1433 | published in | Advances in Therapy | Q4686392 |
| P1476 | title | Fixed-dose combinations for treatment of type 2 diabetes mellitus | |
| P478 | volume | 29 | |